前收市價 | 882.60 |
開市 | 890.40 |
買盤 | 883.20 x 0 |
賣出價 | 883.20 x 0 |
今日波幅 | 881.60 - 894.60 |
52 週波幅 | 504.40 - 932.00 |
成交量 | |
平均成交量 | 2,643,997 |
市值 | 3.935T |
Beta 值 (5 年,每月) | 0.19 |
市盈率 (最近 12 個月) | 44.45 |
每股盈利 (最近 12 個月) | 19.87 |
業績公佈日 | 2024年8月07日 |
遠期股息及收益率 | 12.80 (1.45%) |
除息日 | 2024年3月22日 |
1 年預測目標價 | 918.44 |
According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
In this article, we discuss the 13 best stocks that will always grow. To skip the detailed analysis of the current economic landscape, go directly to the 5 Best Stocks That Will Always Grow. At the Federal Reserve’s May 1 meeting, Chairman Jerome Powell focused on the Fed’s dual mandate of promoting maximum employment and […]
(Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.Most Read from BloombergTruce Talks Drag as Hamas Hits Israel Crossing in Deadly AttackAt $2 Million Per Minute, Treasuries Mint Cash Like Never BeforeJudge Threatens Trump With Jail Over Gag Order ViolationsTreasury Rally Risks Running Into a $125 Billion Brick WallBuffett Praises Apple After Trimming It, Drops Paramount StakeThe shares s